Dr. Zugates is the Vice President of Research and Development for Alivio Therapeutics.  He joins Alivio after spending the last 10 years at Arsenal Medical, a medical device company in Watertown, MA.  During this time, he has been a lead inventor in developing Arsenal’s biodegradable scaffold and in situ foams technology platforms.  He has also played an integral role in translating these technologies toward the clinic for the treatment of cardiovascular disease, intraabdominal hemorrhage, and abdominal aortic aneurysms.  Dr. Zugates started as a Senior Scientist and developed the early device prototypes to achieve pre-clinical proof-of-concept.  More recently, he has served as Senior Manager of Chemistry, where he was responsible for all synthetic and analytical activities at the company.  In this role, he has helped advance Arsenal’s in situ foams devices from the pre-clinical stage through clinical manufacturing and validation.

Prior to joining Arsenal Medical, Dr. Zugates was an National Science Foundation fellow and graduate student in the Langer laboratory at MIT.  His graduate work centered on the development of cationic, biodegradable polymers for gene therapy applications.  His work culminated in the commercialization of two transfection vectors for laboratory use and a preclinical-tested treatment for ovarian cancer that had superior performance to the standard of care drug therapies.

Dr. Zugates received his B.S. in Chemical Engineering from the Pennsylvania State University, where he graduated with highest distinction.  He received his Ph.D. in Chemical Engineering from MIT as an NSF fellow.